Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn’s disease results from a multicentre cohort study /
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2022
|
| Sorozat: | THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
15 No. January-December |
| Tárgyszavak: | |
| doi: | 10.1177/17562848221144349 |
| mtmt: | 33532273 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/25882 |
| Terjedelem/Fizikai jellemzők: | 18 1-18 |
|---|---|
| ISSN: | 1756-283X |